OncologyASCO 2026

Durvalumab + Tremelimumab — EMERALD-3

AstraZeneca

PD-L1 + CTLA-4 + TACE + lenvatinib quad combination in intermediate-stage HCC. EMERALD-3 cohort 1 toplined PFS positive April 2026. ASCO 2026 late-breaker LBA4000. Triplet arm did not hit.

Hepatocellular Carcinoma

Linked Studies

NCT05301842PrimaryACTIVE_NOT_RECRUITINGPHASE3

Evaluate Durvalumab and Tremelimumab +/- Lenvatinib in Combination With TACE in Patients With Locoregional HCC

Hepatocellular CarcinomaUpdated Apr 2026

Loading comments…

Also Known As

Other names

durvalumab

Search all trials →Request coverage update